{"entity":{"id":"bhv-1510","kind":"drug","name":"BHV-1510","aka":["PBI-410","GQ1010"],"tldr":"BHV-1510 is an experimental chemotherapy-delivering antibody being studied alone and with immunotherapy. Early response findings need confirmation in larger trials.","summary":"Biohaven reported an early combination cohort with cemiplimab at the October 10, 2025 cutoff: 23 efficacy-evaluable patients across doses had confirmed ORR 52.2%. A selected 2.5 mg/kg dose group had responses in 3/5 NSCLC, 4/4 endometrial and 1/2 urothelial patients. These very small, uncontrolled populations do not establish superiority over approved ADCs or isolate the ADC contribution from immunotherapy. NCT06384807 registers phase 1/2 testing and identifies PBI-410 and GQ1010 as alternative names.","status":"phase-1","asOf":"2026-10-06","links":[{"label":"Biohaven ESMO IO 2025 sponsor report","url":"https://ir.biohaven.com/news-releases/news-release-details/biohaven-presents-clinical-safety-and-efficacy-data-bhv-1510"},{"label":"ClinicalTrials.gov NCT06384807","url":"https://clinicaltrials.gov/study/NCT06384807"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06384807","nct06464055"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"ADC","payload":"TopoIx (TOP1 inhibitor)","mechanism":"TROP2-directed antibody-drug conjugate delivering a proprietary TOP1 inhibitor payload.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bhv-1510/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"trial":[{"id":"nct06384807","kind":"trial","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","route":"/trials/nct06384807/"},{"id":"nct06464055","kind":"trial","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","route":"/trials/nct06464055/"}]}}